What an FDA Import Alert Is, and What It Does at the Border

Answer first: it lets FDA detain first and examine later

FDA describes import alerts in one sentence on its own page. They are used to protect consumers against products with a history of known violations.

The mechanism is the part worth understanding. FDA can place a product on an import alert after discovering a violation, and then detain future shipments of that product without having to test or otherwise physically examine it.

The agency's shorthand for that is detention without physical exam, abbreviated DWPE. It is the operative consequence of being listed.

So an alert does not describe what is in a particular box. It describes a pattern the agency has already recorded, and it shifts who has to prove what about every box that follows.

The appearance standard, and where it comes from

FDA's page names the source of the authority directly. Section 801 of the Federal Food, Drug, and Cosmetic Act is section 381 of title 21 of the United States Code. FDA says it gives the agency authority to refuse products that appear to be in violation of FDA laws and regulations, and the page calls this the appearance standard.

The statute reads that way on its face. If it appears from the examination of such samples or otherwise that an article falls into one of several listed categories, then the article shall be refused admission.

The listed categories include an article manufactured, processed or packed under insanitary conditions. They include an article forbidden or restricted in sale in the country where it was produced or from which it was exported. And they include an article that is adulterated, misbranded, or in violation of the new drug approval provision.

Read the two verbs together. The finding is that the article appears to fall in a category, and the consequence is refusal. Nothing in that sentence requires the agency to have tested the specific shipment in front of it.

What being on an alert actually changes

FDA states the effect plainly. If a product subject to DWPE is offered for import, it will be detained and refused unless the importer can overcome the appearance of the violation.

The burden moves. Ordinarily an agency acts on what it finds; here the importer has to demonstrate to FDA that the product does not have the violations listed on the import alert.

FDA points to the guidance section of each alert as the place that says what evidence may be appropriate. That is where the practical answer lives, and it varies alert by alert.

The agency also tells importers to check before shipping. Prior to importing into the United States, importers should determine if their products are subject to DWPE, and become familiar with the instructions and possible evidence needed to secure a release.

What an alert document contains

FDA lists the contents in its own fast-facts section, and the list tells you what an alert is for.

Each import alert states the reason for the alert, what products and firms are affected, what FDA laws or regulations appear to have been violated, and other information.

The guidance section carries the operational detail: how DWPE is applied, how to secure the release of a shipment, how to be removed from the alert, and contact information.

The agency also says what an alert is for as a communication. FDA issues import alerts to notify the public, the import community, and FDA staff of the products and firms that appear to be in violation.

Violations can attach to more than a molecule. FDA says they could be related to the product, the manufacturer, the shipper, the importer, the country of origin, or other information.

Red, yellow and green lists, and how to read them backwards

An alert can carry lists, and the lists invert in a way that trips people up. FDA states the rule for each.

Where an alert has a yellow or red list, firms and products that appear on that list are subject to DWPE under the alert. Firms and products not on it are not subject to DWPE under that alert.

Where an alert has a green list, the logic runs the other way. Firms and products on the green list are exempt from DWPE under that alert, and anything not on the green list is not exempt, which means it is subject to DWPE.

That second case is the one to slow down for. On a green-list alert, absence from the list is the adverse position, not the safe one.

How a firm gets off an alert

FDA describes the threshold for removal in general terms. Firms, products and importers become subject to DWPE when there is evidence of a violation of the Act.

For removal, there must be evidence that the conditions that led to DWPE have been resolved, and that future shipments of the product will be safe and compliant. FDA says the evidence will differ depending on the nature of the violation.

The agency points to its Regulatory Procedures Manual, Chapter 9-8, as the document outlining when a product, firm or country may be subjected to DWPE and the general considerations for removal.

FDA also publishes what a removal petition might contain, and the four headings read like a quality investigation. An investigation of how the problem occurred. Corrective actions taken to fix it. Preventive measures to stop it recurring. And evidence, with five clean shipments and a third-party audit given as examples.

For a green-list addition the first heading changes from investigation to analysis: does this problem exist in my product. FDA says it will consider the totality of evidence presented.

What the person holding the shipment can do

Federal regulation sets out a procedure, and it is worth knowing that one exists.

Where it appears that an article may be refused admission, the division director gives the owner or consignee a written or electronic notice saying so and stating the reasons. The notice specifies a place and a period of time during which the owner or consignee has an opportunity to introduce testimony.

That testimony is confined to matters relevant to the admissibility of the article and may be given orally or in writing. On a timely request giving reasonable grounds, the time and place may be changed.

The statute adds a second route. Where an article covered by the misbranding and adulteration clause can, by relabeling or other action, be brought into compliance, a final determination may be deferred. The owner files a written application, executes a bond, and may then be authorized to perform the relabeling under supervision.

If admission is refused and nothing cures it, the article is destroyed unless it is exported within 90 days of the notice of refusal, or within such additional time as the regulations permit. For a drug or device at or below a value threshold set in the statute, destruction may proceed without the export opportunity.

What a listing does not tell you

This is where secondhand accounts go wrong, so it is worth being exact.

The statutory trigger is appearance, not proof. An article appearing to be adulterated or misbranded is refused; the finding is about how the article presents against the law, not a laboratory result on the specific shipment.

A listing is also historical by design. FDA says alerts protect against products with a history of known violations, which means the alert reflects what was found earlier, and the shipment being held may never have been examined at all.

And the violation may have nothing to do with the contents. FDA's own list of what a violation could relate to includes the shipper, the importer and the country of origin. A labeling or promotion problem sits in the same mechanism as a sanitation problem.

So the honest reading is narrow. A listing tells you the agency has a recorded concern attached to a product, firm, shipper, importer or origin, and that shipments will be held until someone rebuts it. It is not a finding about the quality of any particular vial, and it does not settle whether a company is worth buying from.

Limits of what is described here

Two limits belong in front of a reader rather than in a footnote.

No individual import alert is quoted, named or summarized on this page. FDA's alert database is a live search that the agency says is updated in real time, and an alert's lists change. Anything said about a specific alert has to come from that alert on the day you read it.

FDA's own "How to Read an Import Alert" page carries its explanation as graphics rather than text, so its breakdown of the document layout is not described here either.

What is described is the framework: the statutory standard, what DWPE does, what an alert contains, how the lists work, what removal requires, and the notice and hearing procedure attached to a refusal.